4.94
0.11 (2.28%)
| Previous Close | 4.83 |
| Open | 5.02 |
| Volume | 204,473 |
| Avg. Volume (3M) | 285,103 |
| Market Cap | 90,999,248 |
| Price / Earnings (Forward) | 10.44 |
| Price / Sales | 0.980 |
| Price / Book | 0.760 |
| 52 Weeks Range | |
| Earnings Date | 26 Mar 2025 - 31 Mar 2025 |
| Profit Margin | -27.41% |
| Operating Margin (TTM) | -5.03% |
| Diluted EPS (TTM) | -1.34 |
| Quarterly Revenue Growth (YOY) | 30.50% |
| Total Debt/Equity (MRQ) | 31.20% |
| Current Ratio (MRQ) | 3.23 |
| Operating Cash Flow (TTM) | -1.57 M |
| Levered Free Cash Flow (TTM) | 8.35 M |
| Return on Assets (TTM) | -3.27% |
| Return on Equity (TTM) | -20.97% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Health Information Services (US) | Mixed | Bearish |
| Health Information Services (Global) | Mixed | Bearish | |
| Stock | OptimizeRx Corporation | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.0 |
| Insider Activity | 1.5 |
| Price Volatility | 0.5 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | -0.5 |
| Average | 1.20 |
|
OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its products offering are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement. |
|
| Sector | Healthcare |
| Industry | Health Information Services |
| Investment Style | Small Core |
| % Held by Insiders | 13.29% |
| % Held by Institutions | 68.94% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 16.00 (Roth MKM, 223.89%) | Buy |
| Median | 8.00 (61.94%) | |
| Low | 5.00 (Barclays, 1.22%) | Hold |
| Average | 9.19 (86.03%) | |
| Total | 6 Buy, 2 Hold | |
| Avg. Price @ Call | 4.39 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| B. Riley Securities | 24 Dec 2024 | 13.00 (163.16%) | Buy | 4.94 |
| Lake Street | 24 Dec 2024 | 11.00 (122.67%) | Buy | 4.94 |
| Stephens & Co. | 20 Dec 2024 | 5.50 (11.34%) | Hold | 4.91 |
| Barclays | 14 Nov 2024 | 5.00 (1.21%) | Hold | 4.06 |
| JMP Securities | 14 Nov 2024 | 8.00 (61.94%) | Buy | 4.06 |
| RBC Capital | 14 Nov 2024 | 7.00 (41.70%) | Buy | 4.06 |
| Roth MKM | 14 Nov 2024 | 16.00 (223.89%) | Buy | 4.06 |
| Stifel | 14 Nov 2024 | 8.00 (61.94%) | Buy | 4.06 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| FEBBO WILLIAM J | 4.93 | - | 20,000 | 98,600 |
| Aggregate Net Quantity | 20,000 | |||
| Aggregate Net Value ($) | 98,600 | |||
| Aggregate Avg. Buy ($) | 4.93 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| FEBBO WILLIAM J | Officer | 12 Dec 2024 | Buy (+) | 20,000 | 4.93 | 98,600 |
| Date | Type | Details |
|---|---|---|
| 23 Dec 2024 | Announcement | OptimizeRx Announces Departure of CEO William Febbo and Appointment of Stephen Silvestro as Interim CEO |
| 18 Nov 2024 | Announcement | OptimizeRx to Participate in Upcoming Investor Conferences |
| 13 Nov 2024 | Announcement | OptimizeRx Reports Third Quarter 2024 Financial Results |
| 31 Oct 2024 | Announcement | OptimizeRx Sets Third Quarter 2024 Conference Call for November 13, 2024 at 4:30 p.m. ET |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |